These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 33980253)
41. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. Cornillie J; Wozniak A; Li H; Wang Y; Boeckx B; Gebreyohannes YK; Wellens J; Vanleeuw U; Hompes D; Stas M; Sinnaeve F; Wafa H; Lambrechts D; Debiec-Rychter M; Sciot R; Schöffski P Mol Cancer Ther; 2019 Jun; 18(6):1168-1178. PubMed ID: 30962320 [TBL] [Abstract][Full Text] [Related]
42. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409 [TBL] [Abstract][Full Text] [Related]
43. Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry. Mills AM; Beck AH; Montgomery KD; Zhu SX; Espinosa I; Lee CH; Subramanian S; Fletcher CD; van de Rijn M; West RB Am J Surg Pathol; 2011 Apr; 35(4):583-9. PubMed ID: 21412072 [TBL] [Abstract][Full Text] [Related]
44. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085 [TBL] [Abstract][Full Text] [Related]
45. Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. Steele CD; Tarabichi M; Oukrif D; Webster AP; Ye H; Fittall M; Lombard P; Martincorena I; Tarpey PS; Collord G; Haase K; Strauss SJ; Berisha F; Vaikkinen H; Dhami P; Jansen M; Behjati S; Amary MF; Tirabosco R; Feber A; Campbell PJ; Alexandrov LB; Van Loo P; Flanagan AM; Pillay N Cancer Cell; 2019 Mar; 35(3):441-456.e8. PubMed ID: 30889380 [TBL] [Abstract][Full Text] [Related]
46. Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas. Pankova V; Krasny L; Kerrison W; Tam YB; Chadha M; Burns J; Wilding CP; Chen L; Chowdhury A; Perkins E; Lee ATJ; Howell L; Guljar N; Sisley K; Fisher C; Chudasama P; Thway K; Jones RL; Huang PH Clin Cancer Res; 2024 Aug; 30(15):3229-3242. PubMed ID: 38810090 [TBL] [Abstract][Full Text] [Related]
47. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Segal NH; Pavlidis P; Antonescu CR; Maki RG; Noble WS; DeSantis D; Woodruff JM; Lewis JJ; Brennan MF; Houghton AN; Cordon-Cardo C Am J Pathol; 2003 Aug; 163(2):691-700. PubMed ID: 12875988 [TBL] [Abstract][Full Text] [Related]
48. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. Lin DI; Hemmerich A; Edgerly C; Duncan D; Severson EA; Huang RSP; Ramkissoon SH; Connor YD; Shea M; Hecht JL; Ali SM; Vergilio JA; Ross JS; Elvin JA Gynecol Oncol; 2020 May; 157(2):357-366. PubMed ID: 32156473 [TBL] [Abstract][Full Text] [Related]
49. Pleomorphic Sarcomas: The State of the Art. Carvalho SD; Pissaloux D; Crombé A; Coindre JM; Le Loarer F Surg Pathol Clin; 2019 Mar; 12(1):63-105. PubMed ID: 30709449 [TBL] [Abstract][Full Text] [Related]
50. Immune-related prognostic genes signatures in the tumor microenvironment of sarcoma. Wang J; Gong M; Xiong Z; Zhao Y; Xing D Math Biosci Eng; 2021 Mar; 18(3):2243-2257. PubMed ID: 33892543 [TBL] [Abstract][Full Text] [Related]
51. Clinical biomarkers in soft tissue sarcoma A comprehensive review of current soft tissue sarcoma biomarkers. Sharma SR; Paonessa NE; Casadei L; Costas De Faria F; Pollock RE; Grignol V J Surg Oncol; 2022 Feb; 125(2):239-245. PubMed ID: 34586640 [TBL] [Abstract][Full Text] [Related]
52. [Pathological evaluation of soft tissue sarcoma for diagnosis, prognosis and treatment]. Yamaguchi U; Hasegawa T Gan To Kagaku Ryoho; 2004 Sep; 31(9):1340-5. PubMed ID: 15446553 [TBL] [Abstract][Full Text] [Related]
53. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063 [TBL] [Abstract][Full Text] [Related]
54. Chromosome changes in soft tissue sarcomas. Becher R; Wake N; Gibas Z; Ochi H; Sandberg AA J Natl Cancer Inst; 1984 Apr; 72(4):823-31. PubMed ID: 6323809 [TBL] [Abstract][Full Text] [Related]
55. Loss of Expression of a Novel Chromatin Remodeler SMARCA1 in Soft Tissue Sarcoma. Patil PA; Lombardo K; Sturtevant A; Mangray S; Yakirevich E J Cytol Histol; 2018; 9(6):. PubMed ID: 31093468 [TBL] [Abstract][Full Text] [Related]
56. Analysis of gene expression profiles of soft tissue sarcoma using a combination of knowledge-based filtering with integration of multiple statistics. Takahashi A; Nakayama R; Ishibashi N; Doi A; Ichinohe R; Ikuyo Y; Takahashi T; Marui S; Yasuhara K; Nakamura T; Sugita S; Sakamoto H; Yoshida T; Hasegawa T; Takahashi H PLoS One; 2014; 9(9):e106801. PubMed ID: 25188299 [TBL] [Abstract][Full Text] [Related]
57. Clinicopathological characteristics and prognostic factors of T1 (≤5 cm) soft tissue sarcoma -- a comparative study with T2 (>5 cm) soft tissue sarcoma. Kang S; Han I; Lee S; Kim W; Kim H Eur J Surg Oncol; 2014 Apr; 40(4):406-11. PubMed ID: 24388741 [TBL] [Abstract][Full Text] [Related]
58. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188 [TBL] [Abstract][Full Text] [Related]
59. Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. Simon M; Mughal SS; Horak P; Uhrig S; Buchloh J; Aybey B; Stenzinger A; Glimm H; Fröhling S; Brors B; Imbusch CD J Transl Med; 2022 Apr; 20(1):152. PubMed ID: 35366909 [No Abstract] [Full Text] [Related]
60. Spindle cell liposarcoma with a TRIO-TERT fusion transcript. Suster DI; Deshpande V; Chebib I; Taylor MS; Mullen J; Bredella MA; Nielsen GP Virchows Arch; 2019 Sep; 475(3):391-394. PubMed ID: 30793229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]